Cancer Stem Cell and Leukemic CFC Assays

PROVIDED BY REACHBIO

Hematopoietic Cancer Stem Cells and Leukemic Progenitor Cells

For various hematological diseases (e.g. chronic myeloid leukemia, acute myeloid leukemia, multiple myeloma, lymphomas), the molecular abnormalities and perturbed signaling pathways that give rise to these diseases have, in recent years, been elucidated.

In many, if not all forms of cancer, a small number of slowly dividing, self-renewing cancer stem cells give rise to abundant and rapidly dividing diseased cells. Targeted killing of the cancer stem cells, while retaining the normal hematopoietic progenitors, is a new focus of research, aiming to develop more effective and less toxic cancer treatments.

Our assays evaluate and rank the effectiveness of your biotherapeutic candidates at inhibiting cancer stem and progenitor cell expansion and measure functional inhibition of cancer progenitor cell expansion. These assays are useful in evaluating therapies that target cell surface receptors (e.g. CD24) and stem cell-associated signaling pathways (e.g. Wnt/Hedgehog).

Assay Services

PROVIDED BY REACHBIO

AML | Acute Myeloid Leukemia Progenitor Assay

Common Applications for AML-blast like CFC:

Predict compound induced killing
Predict targeted cell killing
Evaluate effects of single agents or combined therapies

ALL | Acute Lymphoblastic Leukemia Progenitor Assay

Common Applications for ALL-CFC:

Predict compound induced killing
Predict targeted cell killing
Evaluate effects of single agents or combined therapies

CML | Chronic Myelogenous Leukemia Progenitor Assay

Applications for CML-CFC:

Predict compound induced killing
Predict targeted cell killing
Evaluate effects of single agents or combined therapies

CLL | Chronic Lymphocytic Leukemia Progenitor Assay

Applications for CLL-CFC:

Predict compound induced killing
Predict targeted cell killing
Evaluate effects of single agents or combined therapies

MM | Multiple Myeloma Progenitor Assay

Common Applications for MM-CFC:

Predict compound induced killing
Predict targeted cell killing
Evaluate effects of single agents or combined therapies

NHL, MCL, DLBCL | Lymphoma Progenitor Assay

Common Applications:

Predict compound induced killing
Predict targeted cell killing
Evaluate effects of single agents or combined therapies

PV | Polycythemia Vera Progenitor Assay

Common Applications for Erythroid Independant CFC proliferation:

Predict compound induced killing
Predict targeted cell killing
Evaluate effects of single agents or combined therapies

AA | Aplastic Anemia Assay

Aplastic anemia is a disease in which the bone marrow, and the blood stem cells that reside there, are damaged. In this disease the marrow microenvironment (bone marrow stroma) on which the cells reside is impaired. The damage may be caused by exposure to chemicals, drugs, radiation, infection or immune disease.

MDS | Myelodysplastic Syndromes

Combination therapies are often use to treat MDS’s which are hematological medical conditions with ineffective production of blood cells. Our assays can asses off-target toxicities.

Did you Know?

Patient Samples and CFU-L Assays

We have the ability to monitor cancer stem cells in patients over the course of a clinical trial using in vitro assays with cells from patients. We can also assess the differential toxicity of compounds on cancer stem cells (leukemic colony forming cells) compared to normal hematopoietic progenitor cells. > Learn more

We can culture various hematopoietic cancer stem and/or progenitor cells in leukemic CFU-L (colony-forming cell) assays and evaluate the effects of test compounds on these cells. CONTACT US to learn more about our assay platform.